AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) 9h - Rachid Ayari steps down as Whole Time Director and CFO effective 30 September 2026.
Source: Bse
Sanofi India Limited (SANOFI)
Small CapPharma stocks · Small cap · NSE
Sanofi India Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result05 Aug, 01:40 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -4.3% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SANOFID candles · FIT view-16.0%Latest close ₹2880.30 on 2026-10-19
Bar
-2.0%
RSI
28
MACD hist
-6.40
52W pos
0%
2026-10-19O ₹2940.00H ₹2940.00L ₹2875.10C ₹2880.30Vol 16,048 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SANOFINifty PharmaNifty 500
- SANOFI
- -15.1%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -9.5 pp
Chart stats
19 Oct 2026- From 52W high
- -41.2%
- 52W range position
- 0%
- ATR (14)
- 2.1%
- Volume vs 20D
- 0.92x
- Avg traded value
- ₹5.4 Cr
- 20D price channel
- ₹2,875.1 - ₹3,220.9
₹4,898
₹2,875.1 - ₹4,898
₹60.9
Latest completed session
20-session average
16.3% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE53
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good60
Revenue +7.9% · PAT +20.0% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model-296.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence72
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 60/100Rev +8% YoY · PAT +20% YoY · margin expansion · operating leverage
Filed 04 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹438 Cr | +7.9% | -7.2% |
| EBITDA | ₹115 Cr | +21.1% | -19.6% |
| Operating margin | 26.0% | +300 bps | -400 bps |
| PAT | ₹84 Cr | +20.0% | -18.4% |
| PAT margin | 19.2% | +194 bps | -264 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 15.80
- P/B
- 8.09
- EV/EBITDA
- 13.23
- Market Cap
- 6965.00Cr
Profitability
- ROE
- 47.10%
- ROCE
- 49.20%
- ROA
- 25.62%
- Dividend Y
- 2.48%
Growth (CAGR)
- Revenue 5Y
- -9.00%
- EPS 5Y
- -9.00%
- Revenue 3Y
- -12.00%
- EPS 3Y
- -12.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 245.50×
- Altman Z
- 7.49
- Book Value
- 374.00
Cash Flow
- FCF Yield
- 4.05%
- FCF Positive Y
- 2/5
- OCF
- 462.00 Cr
- EPS TTM
- 179.70
Shareholding
- Promoter Hold
- 60.40%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 1%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 438-7.2% vs prev
Net Profit
₹ CrLatest: 84.0-18.4% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 28.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~4.5% over last month) — short-term momentum negative.
- RSI(14) at 28 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 53 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 53 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · FAIR VALUEValuation8/30
Growth3/25
Quality20/20
Balance Sheet12/15
Cash Flow6/10
Piotroski
6/9 (+3)
Penalties
1
Raw sum
53
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
53/100 · legacy band FAIR VALUE
Positive drivers
- FCF yield is supportive at 4.0%.
- Quality contributes 20/20 to the score.
- Balance sheet contributes 12/15 to the score.
Main drags
- Fair-value margin of safety is negative at -296.8%.
- Growth is weaker at 3/25; verify the latest quarterly trend.
- Valuation is weaker at 8/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
15.8
PB
8.1
EV/EBITDA
13.2
ROE
47.1%
ROCE
49.2%
FCF Yield
4.0%
Debt/Equity
0.0
MoS
-296.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
53
Previous: 53
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-296.8%
Previous: -305.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
53
53
53
53
53
53
53
53
53
53
53
53
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹1,229.71
-134.2% MoS
Growth-justified P/E
4.0
Growth-justified Value
₹725.99
-296.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INNOVACAP
Small
Innova Captab Limited
Pharmaceuticals
match 167
48
42.6
13.7%
+17%
FAIR VALUE
BLISSGVS
Small
Bliss GVS Pharma Limited
Pharmaceuticals
match 167
39
51.4
11.8%
-8%
WATCHLIST
FDC
Small
FDC Limited
Pharmaceuticals
match 165
40
17.5
11.2%
-180%
WATCHLIST
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 164
40
49.7
11.6%
-8%
WATCHLIST
ZOTA
Small
Zota Health Care LImited
Pharmaceuticals
match 162
26
—
-15.0%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Sanofi India Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
72Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 69th percentile of the scored universe and 58th percentile within Pharma. Main check: results consistency is weak at 22/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
37 docs text-extracted · 19 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
69th percentile
overall median 67 · Pharma: 58th pctile, median 70 · Small: 71st pctile, median 66
Evidence depth
Financial-only
37 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
82
strong · capital discipline
Results
22
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 60.4%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.9%.
- ▸Debt/equity is 0.02.
Trust risks
- ▸1/4 latest quarters had positive YoY revenue growth.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sanofi India Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Directorate 9h - Rachid Ayari to step down as Whole Time Director and CFO on 30 September 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 9h - Rachid Ayari resigns as WTD and CFO effective 30 September 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 20 May - Copies of the Newspaper publication regarding the information on special window for transfer and dematerialisation of physical shares.
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.